{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-242526","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.387305+00:00","generated_at":"2026-06-10T08:32:52.339682+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed","bullets":["Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.","Cash and equivalents $100.7M, no debt; cash used in operations $52.5M.","Stockholders rejected Infinity Pharmaceuticals merger (47.86% for, 51.44% against); agreement terminated.","David M. Urso appointed CEO (June 2023); Jay File appointed CFO (effective Aug 2023).","Voruciclib+venetoclax data early 2024; ME-344+bevacizumab data H1 2024; workforce reduced 61% to 41 employees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-242526","json":"https://secwatch.observer/filing/0001193125-23-242526.json","markdown":"https://secwatch.observer/filing/0001193125-23-242526.md","text":"https://secwatch.observer/filing/0001193125-23-242526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523242526/0001193125-23-242526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523242526/d548878d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:32:52.339682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcdfea301e6f98610ace91c6b3b287e3ecabb2d0","claim":"Lite Strategy, Inc. reported financial results for fiscal year ended June 30, 2023.","evidence_excerpt":"On September 26, 2023, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal year ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523242526/0001193125-23-242526-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}